Clinical trials: Patients With Major Depressive Disorder
Bipolar I Disorder
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like flipping a coin) to either active drug (LB-102 or placebo).
- Trial name
- Illuminate1 (NCT07494305)
- Testing
- LB-102
- Where
- 26 sites in United States
- Volunteers
- 320 people
- Sponsor
- LB Pharmaceuticals Inc.
Major Depressive Disorder
Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy and safety of NRX-1074 following a single intravenous dose in subjects with major depressive disorder.
- Trial name
- NCT02067793
- Testing
- NRX-1074 1 mg, NRX-1074 5 mg, NRX-1074 10 mg
- Where
- 12 sites in United States
- Volunteers
- 151 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Depressive Disorder, Major
A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder
This study evaluates the efficacy, safety and tolerability of levomilnacipran extended-release (ER) compared with placebo in the prevention of depression relapse in major depressive disorder (MDD).
- Trial name
- NCT02288325
- Testing
- Levomilnacipran ER
- Where
- 47 sites in United States
- Volunteers
- 644 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder (MDD)
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This is a multicenter, 52-week, open-label study designed to assess the safety and tolerability of an oral aripiprazole/escitalopram combination therapy in outpatients with major depressive disorder (MDD).
- Trial name
- NCT01123707
- Testing
- Aripiprazole, Escitalopram
- Volunteers
- 173 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior
The purpose of this study is to learn about: To evaluate the efficacy of PRT-042 nasal spray for the Rapid Reduction of the depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or…
- Trial name
- NCT07193901
- Testing
- Low Dose PRT042 nasal spray, median Dose PRT042 nasal spray, high dose PRT042 nasal spray
- Where
- 15 sites in China
- Volunteers
- 98 people
- Sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.
Major Depressive Disorder
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders
The purpose of this study is to evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in patients with MDD with inadequate response to an antidepressant treatment.
- Trial name
- PEARL (NCT00326105)
- Testing
- Quetiapine fumarate
- Where
- 56 sites in United States
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder
This study aims at evaluating the effect of vortioxetine on cognitive dysfunction in major depressive disorder (MDD) patients with inadequate response to current antidepressant treatment.
- Trial name
- NCT02272517
- Testing
- Vortioxetine 10-20 mg, Escitalopram 10-20 mg
- Where
- 16 sites in Finland, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Major
Study of Rapastinel as Monotherapy in Patients With MDD
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) and 900 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).
- Trial name
- NCT03560518
- Testing
- Rapastinel
- Where
- 40 sites in United States
- Volunteers
- 439 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
To evaluate the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR) in the treatment of Major Depressive Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation.
- Trial name
- AMBER (NCT00351169)
- Testing
- Quetiapine SR, Escitalopram
- Where
- 42 sites in Canada, China and 7 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Healthy Volunteers (Part 1), Major Depressive Disorder (Part 2)
Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder
This is a two part study. The objective of Part 1 is to evaluate the safety, tolerability, and pharmacokinetics of HT-2157 in healthy normal volunteers Part 2 is a randomized, double-blind, placebo-controlled, multiple (21-day)…
- Trial name
- NCT01413932
- Testing
- HT-2157
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dart NeuroScience, LLC
Major Depressive Disorder
Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
To examine the safety and efficacy of long term administration of aripiprazole as an adjunctive therapy, co-administered with either a selective serotonin reuptake inhibitor (SSRI) or a selective-norepinephrine reuptake inhibitor…
- Trial name
- NCT00882362
- Testing
- OPC-14597 (Aripiprazole)
- Where
- 8 sites in Japan
- Volunteers
- 155 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Insomnia, Major Depressive Disorder
The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy
The purpose of this study is to investigate exploratorily the effect of ramelteon 8 mg once daily for 8 weeks in the treatment of insomnia patients with depression by using actigraphy.
- Trial name
- NCT02669082
- Testing
- Ramelteon
- Where
- 7 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Takeda
Major Depressive Disorder
A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression
The purpose of this study is to assess the efficacy of esketamine compared with placebo in improving symptoms of depression in patients with treatment resistant depression.
- Trial name
- NCT01640080
- Testing
- Esketamine
- Where
- 9 sites in Belgium, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Janssen Research & Development, LLC
Bipolar Depression, Major Depressive Disorder
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or…
- Trial name
- NCT04285515
- Testing
- Lumateperone
- Where
- 42 sites in United States, Bulgaria and 3 more
- Volunteers
- 488 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder Co-Occurrent With Anxiety, Adult Patients
First choIce Antidepressants: General Practitioner's Treatment Approach in the Czech Republic
According to the local guidelines (Recommendation for General Practitioners), the first choice Anti-Depressant (AD) in Major Depressive Disorder (MDD) in primary care should be selective serotonin reuptake inhibitors (SSRI), e.g.
- Conditions
- Major Depressive Disorder Co-Occurrent With Anxiety, Adult Patients, Newly Diagnosed Depression
- Trial name
- FIAT (NCT05291897)
- Where
- 6 sites in Czechia
- Volunteers
- 28 people
- Sponsor
- Angelini Pharma Česká republika s.r.o.
Depressive Disorder, Major
Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder
The primary objective is to examine changes in pre/post-augmentation healthcare costs and resource utilization in patients diagnosed with major depressive disorder (MDD) who augment their current antidepressant therapy with an…
- Trial name
- NCT01145313
- Volunteers
- 501 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran ER relative to placebo in adolescent outpatients (12-17 years) with Major Depressive Disorder (MDD).
- Trial name
- NCT02431806
- Testing
- Levomilnacipran, Fluoxetine
- Where
- 49 sites in United States, Puerto Rico
- Volunteers
- 552 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes
This study will evaluate the efficacy of Vortioxetine in the prevention of relapse of major depressive episodes in patients who responded to open-label treatment with Vortioxetine.
- Trial name
- NCT00596817
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 639 people
- Sponsor
- H. Lundbeck A/S
Unipolar Depression, Major Depressive Disorder (MDD)
Validation of EmoDTx as a Digital Endpoint for Mood Monitoring in Adult Patients Suffering From Unipolar Depression
The aim of this study is to validate the EmoDTx as a digital tool for mood monitoring in adult patients with unipolar depression. The study is prospective, multicenter, and observational, with a single-arm approach.
- Conditions
- Unipolar Depression, Major Depressive Disorder (MDD), Depression
- Trial name
- EMC2FR (NCT06860165)
- Where
- 2 sites in France
- Volunteers
- 98 people
- Sponsor
- Emobot
Depressive Disorder
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of SR58611A in elderly patients with depression.The primary objective is to evaluate the efficacy of a 700 mg dose of SR58611A compared to placebo in elderly…
- Trial name
- ZEPHIR (NCT00319709)
- Testing
- SR58611A
- Where
- 5 sites in Bulgaria, Finland and 3 more
- Volunteers
- 288 people
- Sponsor
- Sanofi